Global Pharma Health Care Private Limited

Global Pharma Healthcare Private Limited, established in 1986, is a privately held Indian pharmaceutical company headquartered in Chennai, Tamil Nadu. The company is registered under the Corporate Identification Number (CIN) U51102TN1986PTC013099. As of March 31, 2022, Global Pharma reported a paid-up capital of ₹116,009,900, with an authorized capital of ₹125,000,000. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

Global Pharma's product portfolio is diverse, encompassing over 450 pharmaceutical solutions. These products are manufactured in facilities certified by the European Union Good Manufacturing Practice (EU-GMP) and the World Health Organization Good Manufacturing Practice (WHO-GMP), ensuring adherence to international quality standards. The company's manufacturing plant, located in the SIDCO Pharmaceutical Complex in Alathur, Tamil Nadu, spans over 75,000 square feet and is powered entirely by solar energy, reflecting its commitment to sustainability.

Global Pharma's primary manufacturing facility is situated in the SIDCO Pharmaceutical Complex in Alathur, Tamil Nadu. This state-of-the-art plant covers more than 75,000 square feet and is designed for large-scale, precision-controlled pharmaceutical production. The facility operates entirely on solar energy, underscoring the company's dedication to sustainable manufacturing practices. It is certified by both EU-GMP and WHO-GMP, ensuring compliance with stringent international quality standards. The plant's proximity to the port of Chennai facilitates efficient logistics and distribution, enhancing the company's export capabilities.

The leadership team at Global Pharma Healthcare Private Limited is headed by Dr. A.R. Venkatesh, who serves as the Chief Executive Officer (CEO). Under his guidance, the company has expanded its global footprint, delivering pharmaceutical solutions to over 40 countries. The Chief Financial Officer (CFO) and other key executives play pivotal roles in overseeing the company's financial operations and strategic initiatives, contributing to its sustained growth and market presence.

Global Pharma Healthcare Private Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold certifications from EU-GMP and WHO-GMP, facilitating product registrations and approvals in these regions. In the United States, the company faced a warning letter from the FDA on October 20, 2023, citing violations of Current Good Manufacturing Practice (CGMP) regulations during an inspection conducted from February 20 to March 2, 2023. This incident underscores the importance of maintaining stringent quality control measures to ensure compliance with regulatory standards in these markets.

Global Pharma Healthcare Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's extensive product registrations and regulatory approvals from various Ministries of Health worldwide have facilitated its entry into these regions. Additionally, the company's WHO-GMP certification enhances its credibility and acceptance in these markets, enabling access to a broader patient base seeking affordable and high-quality pharmaceutical products.

Global Pharma Healthcare Private Limited's geographic strategy involves a balanced approach to market diversification and risk management. By exporting to over 40 countries, the company mitigates concentration risk and leverages growth opportunities across different regions. The company's manufacturing facility in Chennai, India, serves as a strategic hub, facilitating efficient logistics and distribution to various markets. This strategic direction positions Global Pharma to adapt to global market dynamics and meet the diverse needs of its international clientele.

Global Pharma Healthcare Private Limited's manufacturing facility in Alathur, Tamil Nadu, is registered with the U.S. Food and Drug Administration (FDA). However, the company received a warning letter from the FDA on October 20, 2023, citing violations of Current Good Manufacturing Practice (CGMP) regulations during an inspection conducted from February 20 to March 2, 2023. This warning letter highlights the need for the company to address the identified deficiencies to maintain its FDA registration and continue exporting to the U.S. market.

Global Pharma Healthcare Private Limited's manufacturing facilities are certified by both the World Health Organization Good Manufacturing Practice (WHO-GMP) and the European Union Good Manufacturing Practice (EU-GMP). These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing. The WHO-GMP certification, in particular, enhances the company's credibility in global markets, facilitating product registrations and approvals across various countries.

In India, Global Pharma Healthcare Private Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing facility in Alathur, Tamil Nadu, holds the necessary licenses and approvals from the CDSCO, ensuring compliance with national pharmaceutical manufacturing standards. Additionally, the company's state-of-the-art facility is powered entirely by solar energy, reflecting its commitment to sustainable manufacturing practices.

On October 20, 2023, Global Pharma Healthcare Private Limited received a warning letter from the U.S. Food and Drug Administration (FDA) concerning violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA inspection, conducted from February 20 to March 2, 2023, identified deficiencies in the company's manufacturing processes. This warning letter underscores the importance of maintaining stringent quality control measures to ensure compliance with regulatory standards in the U.S. market.

In the pharmaceutical export sector, Global Pharma Healthcare Private Limited faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical exporters and multinational corporations with a strong presence in global markets. The company's focus on high-quality manufacturing, as evidenced by its EU-GMP and WHO-GMP certifications, positions it favorably in the market. However, the recent FDA warning letter may impact its competitive standing, necessitating prompt corrective actions to maintain market share.

Global Pharma Healthcare Private Limited's key differentiators include its extensive product portfolio, encompassing over 450 pharmaceutical solutions across various therapeutic areas. The company's manufacturing facilities are certified by EU-GMP and WHO-GMP, ensuring adherence to international quality standards. Additionally, the facility's operation on 100% solar energy reflects a commitment to sustainability. These factors collectively contribute to the company's reputation as a reliable and quality-focused pharmaceutical exporter.

Global Pharma Healthcare Private Limited's strategic direction focuses on expanding its global footprint by exporting to over 40 countries. The company's manufacturing facility in Chennai, India, serves as a strategic hub, facilitating efficient logistics and distribution. The recent FDA warning letter highlights the need for the company to address identified deficiencies to maintain its position in the U.S. market. Moving forward, the company is likely to emphasize strengthening its quality control measures and regulatory compliance to sustain its competitive edge.

Global Pharma Healthcare Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a diverse product portfolio and a global presence. The company's manufacturing facility is certified by EU-GMP and WHO-GMP, ensuring adherence to international quality standards. However, the recent FDA warning letter indicates areas for improvement in quality control processes. Prospective partners should assess the company's commitment to addressing these issues and its capacity to meet supply demands reliably.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Verify the World Health Organization Good Manufacturing Practice certification to ensure adherence to international quality standards.

• EU-GMP Certification: Check the European Union Good Manufacturing Practice certification for compliance with European pharmaceutical manufacturing standards.

• ISO Certifications: Ensure the company holds relevant ISO certifications, such as ISO 9001:2015 for quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

Prospective partners should undertake the following due diligence steps: